Form 4: Cue Biopharma Executive Granted Stock Options
Statement of Changes in Beneficial Ownership
Cue Biopharma reports a stock option grant to Chief Business Officer Lucinda Warren, with vesting over four years.
Summary
- Lucinda Warren, Chief Business Officer at Cue Biopharma, Inc., was granted stock options on April 9, 2026.
- The options represent the right to purchase 250,000 shares of common stock at an exercise price of $0.29 per share.
- These options are exercisable starting April 8, 2036.
- The options vest over a four-year period, with 25% vesting one year after the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard executive stock option grant without immediate financial impact or significant strategic news.
Positives
- Grant of stock options to a key executive, indicating a commitment to incentivize leadership.
- The option grant aligns executive interests with long-term shareholder value through potential stock appreciation.
Future Outlook
The filing details the terms of a stock option grant, which is a form of future compensation contingent on continued service and vesting schedules. The exercise date is set for April 8, 2036, indicating a long-term incentive.
Industry Context
StockSavvy.ai notes that executive stock option grants are a common practice in the biopharmaceutical industry to attract, retain, and motivate key talent, aligning their financial interests with the company's performance and long-term growth prospects.
Stakeholder Impact
- Shareholders: The grant of options represents potential future dilution if exercised, but also serves as a retention tool for key management, which can be beneficial for long-term company strategy.
- Employees: Signals a focus on executive compensation and retention within the company.
- Management: Lucinda Warren benefits from a long-term incentive tied to company performance.
Next Steps
- Vesting of stock options over a four-year period.
- Potential exercise of stock options on or after April 8, 2036.
Key Dates
| Date | Description |
|---|---|
| 04/09/2026 | Date of earliest transaction (grant date of stock options) |
| 04/08/2036 | Expiration date of the stock options |
| 04/10/2026 | Date of report signature |
Keywords
stock options, executive compensation, Cue Biopharma, CUE, Form 4, beneficial ownership, equity award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.